

AUTHOR INDEX

VOLUME 28

- Acar, J. F., 458
 Acevedo, Hernan F., 589
 Acevedo, Hernan O., 589
 Ackerman, Valentine P., 96
 Actis, Luis A., 176
 Adloff, Michel, 311
 Ahmedy, Ali, 351
 Alaghamandan, Hassan, 375
 Aldridge, Kenneth, 675
 Aldridge, Kenneth E., 634
 Alvarez, Salvador, 689
 Amend, William, 535
 Andrews, Richard J., 815
 Anwar, Hosmin, 195
 Arai, Tadashi, 5
 Ariza, J., 548
 Ashby, J., 425
 Asmar, Basim I., 138
 Asselman, Chantal, 378
- Baars, Anita M., 654
 Bailey, Denis M., 786
 Bakker-Woudenberg, Irma A. J. M., 654
 Baldwin, William W., 626
 Baquero, Fernando, 113
 Barbeau, Gilles, 713
 Barriere, Steven L., 55
 Barry, D. W., 181
 Bartlett, Karen H., 842
 Barton, Nancy, 265
 Barug, Daniel, 643
 Bayer, Arnold S., 51, 781
 Benjamin, Irving S., 778
 Bergeron, Michel G., 123, 320, 349, 404, 713
 Berk, Steven L., 689
 Berkowitz, Frank E., 207
 Berman, Jonathan D., 723
 Bien, Paul A., 766
 Bihl, Julie, 133
 Biron, K. K., 181
 Bittner, Marvin J., 299
 Blaser, Jürg, 64
 Blenkarn, J. Ian, 778
 Blickle, Jean-Frédéric, 311
 Bloomfield, Sally F., 289
 Blumer, Jeffrey L., 839
 Blumgart, Leslie H., 778
 Bodet, C. Adrien, III, 437
 Boehme, Richard, 240
 Bolard, Jacques, 167
 Bornemann, L. D., 46
 Bosso, John A., 829
 Bothof, Theo, 824
 Bouvet, Anne, 607
 Bouza, Emilio, 222
 Brajtburg, Janina, 144
 Brammer, Keith W., 815
 Bran, Jose Luis, 128
 Brander, Elias E., 157
 Branger, C., 458
 Brideau, Roger J., 485
 Brocks, V. M., 46
 Brogard, Jean-Marie, 311
 Brown, Allen L., 791
 Brown, Michael R. W., 195
 Brunham, Robert C., 393
 Brunson, Kenneth W., 626
 Bryan, Joe P., 361
- Buccini, Frank, 601
 Buck, R. E., 761
 Buckley, Joyce A., 138
 Burge, Lurinda J., 698
 Burnham, W. R., 211
 Burns, William H., 740
 Butzler, Jean-Paul, 378
 Buu-Hoi, A., 458
 Bygdeman, Solgun, 393
 Byrd, Richard G., 33
- Cafferkey, Mary T., 819
 Calia, Frank M., 735
 Call, Evan W., 375
 Cameron, Fiona H., 96
 Carbon, Claude, 607
 Cardines, Rita, 847
 Carlier, Cécile, 421
 Caron, Michel, 123
 Carr, Daniel J. J., 578
 Carr, Michael E., 413
 Casin, Isabelle M., 315
 Cerruti, Richard L., 1
 Chalkley, L. J., 331
 Chan, Lap-Yu, 274
 Chapman, Michael, 165
 Chau, P. Y., 461
 Chen, Ming S., 740
 Cheng, Nick, 842
 Cheng, Yuan Rong, 678
 Chernow, Marlene, 240
 Cherubin, Charles, 601
 Chisholm, D. R., 761
 Chong, Yunsop, 282
 Chow, Anthony W., 842
 Chu, Kin-Wah, 639
 Chumpitaz, Jorge C., 452
 Chung, Hee-Young, 282
 Citron, Diane M., 160
 Clark, Nancy C., 154
 Cleary, Timothy, 675
 Cohen, Michael A., 766
 Colacino, Joseph M., 252
 Coleman, David C., 413
 Collatz, Ekkehard, 315
 Colley, Nigel, 165
 Cone, Lawrence A., 33
 Congeni, Blaise L., 508
 Connell, Edward V., 1
 Conrad, Dennis A., 58
 Contrepoint, Alain, 607
 Cook, P. Dan, 375
 Cooksey, Robert C., 154
 Cotter, Julie L., 118
 Courvalin, Patrice, 421
 Cowan, Ronald I., 839
 Cox, Phyllis A., 508
 Creger, Richard J., 839
 Cremieux, Anne C., 607
 Crokaert, F., 756
 Cronberg, Stig N., 12
 Crosa, Jorge H., 176
 Cuchural, George J., Jr., 675
 Cunningham, Eloise J., 21
 Cushion, Melanie T., 796
 Cynamon, Michael H., 440
- Dajani, Adnan S., 138
 Daly, Judy A., 343
 Danziger, Larry H., 839
- da Silva, H. R., 36
 Davis, Robin, 74
 Davis, S. S., 211
 De Clercq, Erik, 84, 246
 de Groot, Kees, 643
 de la Torre, Manuel Gardía, 222
 Delgado, Timothy F., 589
 Delmas, Claude L., 351
 de Neeff, Janine, 824
 Dent, J., 837
 de Pauw, Ben, 824
 Desrochers, Carmen, 711
 de Witte, Theo, 824
 Dick, James D., 597
 Domagala, John M., 766
 Dominguez-Gil, A., 544
 Donta, Sam T., 500
 Doraiswamy, Brinda, 508
 Dougherty, Thomas J., 90, 200
 Dowling, John N., 730
 Drusano, George L., 442
 Drusano, G. L., 235
 Drutz, David J., 437
 Dubost, Maurice, 630
 duBouchet, Lorraine, 508
 Dulworth, Jacqueline K., 745
 Durack, David T., 751
 Duran, S., 235
 Duval, Jean, 421
- Ederer, Mary N., 381
 Elharrif, Zoubida, 695
 Eliopoulos, George M., 78, 514
 Ellis, M. N., 181
 Eng, Robert H. K., 601
 Engle, Jeannette C., 146
 Eron, Lawrence J., 308
 Evans, Hugh E., 149
 Evans, Martin E., 41
- Fader, Robert C., 118
 Falkner, Frederick R., 413
 Fan, Sheung-Tat, 639
 Fang, L. S. T., 46
 Fass, Robert J., 834
 Federspiel, Charles F., 41
 Feingold, David S., 532
 Fennell, Cynthia L., 188
 Fernández-Viladrich, P., 548
 Finegold, Sydney M., 675
 Fitzgerald, Faith T., 347
 Fleishaker, J. C., 369
 Flores, Becky M., 188
 Flynn, Neil M., 347
 Fontana, Roberta, 678
 Forrest, A., 235
 Forsgren, Arne B., 12
 Foster, Timothy J., 413
 Foucault, Paule, 349
 Foudin, Rochelle, 612
 Franssen, Lieve, 393
 Freeman, Donna J., 103
 Freitas, Vicki R., 240
 Froila, Frank N., 730
 Fujita, Kiyo, 15
 Fukuda, Yoshiaki, 15
 Fulton, Robert W., 698
- Furman, P. A., 181
- Galeazzi, Luciano, 419
 Gallalee, James V., 723
 Gambertoglio, John, 535
 Ganzinger, U., 473
 Garcia, Juan F., 128
 Garden, G. M. F., 425
 Garty, Moshe, 489
 Gary-Bobo, Claude M., 167
 Gerding, D. N., 849
 Ghazzouli, Ismail, 740
 Gianfrilli, Paola, 847
 Gibson, Robert N., 778
 Ginsburg, Charles M., 504
 Giovenella, A. J., 660
 Giunta, Sergio, 419
 Glupczynski, Y., 756
 Goldstein, Ellie J. C., 160
 Goldstein, Fred, 452
 Gonzalez, M. A., 235
 Gooch, W. Manford, III, 343
 Gootz, Thomas D., 69
 Gorbach, Sherwood L., 675
 Gordon, Katherine P., 69
 Gordts, Bart, 378
 Gotz, Vincent P., 727
 Grappel, Sarah F., 660
 Gratz, Jean C., 428
 Grégoire, Sylvie, 123
 Griffin, Hugh B., 413
 Griffin, Timothy J., 766
 Groner, Michael C., 64
 Groppa, Giuseppe, 419
 Grossato, Anna, 678
 Gudiol, F., 548
 Guerrero, Antonio, 222
- Haag, Ranier, 456
 Haanen, Clemens, 824
 Haataja, H., 812
 Habib, Nagy, 778
 Hall, Leo M., 265
 Haller, I., 663
 Hammerschlag, Margaret R., 508
 Hara, Kohei, 15
 Hardisson, C., 163
 Hare, Roberta S., 282
 Harvey, Lisa, 308
 Haslberger, A., 473
 Hayden, Frederick G., 216
 Heifets, Leonid B., 570
 Heifetz, Carl L., 766
 Hellin, Teresa, 222
 Helsel, Valerie L., 834
 Hemelhof, Wim, 378
 Henry, D., 259
 Herbst, John J., 829
 Herndon, David N., 118
 Hill, Gail, 675
 Hirschman, Shalom Z., 706
 Hitzig, W. H., 667
 Hixon, Deborah L., 308
 Hoffman, Howard E., 216
 Höger, P. H., 667
 Holdrinet, Rob, 824
 Holmes, King K., 141, 188
 Holzoffer, Sonja, 456
 Hone, Rosemary, 819

- Hoogmartens, Jos, 630
 Hooper, David C., 581, 716
 Hopfer, Roy L., 511
 Horowitz, Edward A., 299
 Houang, Elizabeth T., 165
 Howard, Jorge, 282
 Hsieh, Wei-Chuan, 282
 Huffman, John H., 375
 Humphrey, M. J., 648
 Huovinen, Pentti, 354
 Huovinen, Saara, 354
 Hurwitz, Aryeh, 489
 Hylands, Peter J., 289
- Iannini, Paul, 675
 Ikewaki, Nobunao, 28
 Inamine, Edward, 478
 Ingólfssdóttir, Kristín, 289
 Inoue, Kunio, 684
 Inoue, Matsuhisa, 684, 773
 Inoue, Michiko, 192
 Iseman, Michael D., 570
 Ito, Hideharu, 192
 Izumikawa, Kinichi, 15
- Jackson, Julius H., 21
 Jacobs, Richard F., 791
 Jacobus, Nilda V., 675
 Jacoby, George A., 703
 Janda, J. Michael, 151
 Janney, Aileen, 634
 Jehl, François, 311
 Jevons, S., 648
 John, Lindsay, 778
 Johnson, David E., 735
 Johnson, Jonas T., 832
 Jokipii, Anssi M. M., 561
 Jokipii, Liisa, 561
 Jones, Fred, 21
 Jones, Mary, 689
 Jones, Steven, 832
 Jones, Terry E., 293
 Jordan, M. Colin, 172
 Jorgensen, James H., 437
 Juliano, Rudolph L., 511
 Juncosa, Teresa, 357
- Kadurugamuwa, Jagath L., 195
 Kakizawa, Hiromi, 773
 Kanes, Wanda, 570
 Kania, Stephen A., 107
 Karachalios, George N., 693
 Keane, Conor T., 819
 Kearns, Gregory L., 791
 Keller, P. M., 181
 Kenny, George E., 141
 Kenny, Michael T., 745
 Khan, Abdul J., 149
 Kibwage, Isaac Ongubo, 630
 Kim, Ha-Kyung Cho, 832
 Kim, Kwang Sik, 51, 389, 433, 781
 Kiminki, Olli, 354
 Kingsbury, William D., 494
 Klasterksy, J., 467
 Kliebe, Christine, 302
 Kluza, Ronald B., 791
 Kobayashi, George S., 144
 Kobayashi, Yoshie, 514
 Kobos, Denise M., 138
 Koga, Hironobu, 15
 Koldin, Malcolm H., 144
- Kondo, Hisao, 684
 Koornhof, H. J., 331
 Koskela, Markku, 354
 Koup, Jeffrey R., 74
 Koutsky, Laura A., 141
 Kratz, Luisa, 612
 Kubo, Hiroaki, 514
 Kumada, Teppei, 282
 Kumar, Kusum, 149
- Lally, Richard T., 381
 Lam, Selina, 540
 Lamesch, Catherine, 607
 Langford, Marilyn P., 578
 Larsson, Sture, 12
 Latorre, Cristina, 357
 Lau, Wan-Yee, 639
 Lavoie, Gaétan Y., 320, 404
 Lawrence, Françoise, 528
 LeBel, Marc, 123, 713
 LeBlanc, Donald J., 141
 Leclercq, Roland, 421
 Lee, How-Sung, 540
 LeFrock, Jack L., 133
 Legrand, J. C., 467
 Lehrman, S. N., 181
 Leitner, F., 761
 Lelievre-Pegorier, Martine, 565
 Lembke, Lois A., 500
 Lessard, Céline, 349
 Lett, Marie-Claire, 351
 Leung, Y. K., 461
 Levi, Michael A., 730
 Levin, Myron J., 207
 Levot, Georgette, 630
 Levy, Patrick, 311
 Lifland, Patti W., 146
 Lilley, Cynthia, 118
 Lindholm-Levy, Pamela J., 570
 Linke, Michael J., 796
 Lior, Hermy, 708
 Lismont, M. J., 756
 Llana, J., 163
 Lopez, Carlos, 252
 Lopez-Berestein, Gabriel, 511
 Luzzi, Ida, 847
- Maeda, Akio, 5
 Magana, J. L., 235
 Männistö, P. T., 812
 Marchand, Anne-Marie, 695
 Mariño, E. L., 544
 Marks, Melvin I., 58
 Marriott, Michael S., 815
 Martin, J. L., 181
 Martínez-Beltrán, Jesús, 222
 Martínez-Suárez, Joaquín V., 113
 Maserati, Renato, 428
 Matsen, John M., 829
 Matsuda, Kouji, 684
 Matsushita, Kazuko, 227
 Matthews, Thomas R., 240
 Mattick, John S., 96
 Mattila, Timo, 354
 McCann, William P., 265
 McCarthy, Peter J., 494
 McCracken, George H., Jr., 504
 McDevitt, David A., 730
 McKinley, Geoffrey, 151
- McLaren, Colin, 740
 McNamara, P. J., 369
 McNulty, C. A. M., 425
 McNulty, Clodna A. M., 837
 McPherson, Gilbert A. D., 778
 Medoff, Gerald, 144
 Mégraud, Francis, 695
 Mehta, Kapil, 511
 Mehta, Reeta T., 511
 Mejia, Carlos R., 128
 Mendoza, M. C., 163
 Merlet-Benichou, Claudie, 565
 Meulemans, Alain, 565
 Meunier-Carpentier, F., 467
 Meyer, Joachim F., 302
 Meyer, Richard, 478
 Meyers, Burt R., 706
 Michel, Marc F., 654
 Mikami, Yuzuru, 5
 Miller, George H., 282
 Milne, Robert W., 293
 Minami, Shinzaburo, 773
 Minocha, Anil, 216
 Misiek, M., 761
 Mitsuhashi, Susumu, 684, 773
 Moellering, Anne E., 514
 Moellering, Robert C., Jr., 78, 514
 Moestrup, Torkil, 12
 Mok, Daniel, 778
 Monteil, Henri, 311
 Monteiro, Edmund H., 540
 Moody, J. A., 849
 Moranchel, A. H., 235
 Mordenti, Joyce, 55
 Morikawa, Masako, 192
 Morningstar, Jean, 172
 Morris, J. Glenn, Jr., 442
 Motyl, Mary R., 151
 Mudaliar, Yogan, 293
- Nagasawa, Masao, 15
 Nahmias, André J., 552
 Nakayama, Chikao, 326
 Nakazato, Hiroko, 15
 Nearman, Howard S., 839
 Newman, David J., 494
 Ng, Lai-King, 708
 Ng, W. S., 461
 Ngui-Yen, J., 259
 Nies, Berthold A., 302
 Nisbet, L. J., 660
 Nisbet, Louis J., 494
 Nishikawa, Takashi, 514
 Nishiyama, Yukihiko, 326
 Norman, Dean, 781
 Nsanze, Herbert, 393
- Øie, Svein, 535
 Obbink, Derk J. Groot, 96
 O'Brien, J., 211
 Oka, Kitaro, 192
 O'Keefe, J. Paul, 675
 Olson, Kurt, 504
 Ozasa, Diane C., 55
- Painter, B., 235
 Pallarés, R., 548
 Pantosti, Annalisa, 847
 Paolantonacci, Philippe, 528
 Pardo, Matias, 589
 Pascal, Claude, 630
- Pasculle, A. William, 730
 Patel, I. H., 46
 Patterson, Lyndell S., 41
 Paulin, Lars G., 157
 Pérez-Díaz, J. Claudio, 113
 Perfect, John R., 751
 Peters, Jeanne, 552
 Peterson, L. R., 849
 Petitjean, Pierre, 630
 Petruska, Mary, 504
 Phillips, L., 660
 Pichardo, A., 235
 Pierson, Carl, 675
 Piot, Peter, 393
 Pitkin, D. H., 660
 Plorde, James J., 69
 Plummer, Francis, 393
 Polis, Michael A., 576
 Ponte, Carmen, 845
 Poretz, Donald M., 308
 Pösö, Hannu J., 157
 Preheim, Laurel C., 299
 Price, K. E., 761
 Proctor, Richard A., 691
 Pugsley, Mary P., 299
 Pulkkinen, Leena, 354
 Pursiano, T. A., 761
- Raikow, Radmila B., 589
 Ramirez, Claudio A., 128
 Rapp, Fred, 449
 Reig, Milagro, 113
 Reiszner, Edina, 514
 Rice, Vicki, 552
 Richardson, Kenneth, 815
 Ritchie, Lyndal J., 96
 Robert-Géro, Malka, 528
 Roberts, Marilyn C., 141, 176
 Robins, Roland K., 375
 Rocha, Heonir, 361
 Rodriguez-Barbero, J., 544
 Rodriguez-Crèixems, Marta, 222
 Roets, Eugene, 630
 Romero-Vivas, José, 222
 Rosenfeld, Warren, 149
 Rosenwirth, Brigitte, 246
 Rossan, Richard N., 612
 Rossi, Lucia, 678
 Roy, Réjean, 349
 Rubin, R. H., 46
 Ruff, G., 548
- Sabatelli, Frank J., 282
 Safranek, Thomas J., 299
 Saikawa, Isamu, 773
 Saito, Atsushi, 15
 Saito, Kazuhisa, 28
 Saito, Saburo, 28
 Sakly, Rachid, 565
 Salas, J. A., 163
 Sampaoli, Giuseppe, 419
 Sande, Merle A., 361
 Sanders, Charles V., 634
 Sanders, Christine C., 299
 Saneyoshi, Mineo, 326
 Sanfeliu, Isabel, 357
 Sansom, Lloyd N., 293
 Sanson-Le Pors, Marie-Jose, 315
 Santamaría, Margarita, 845
 Saral, Rein, 740
 Sasaki, Kazumi, 684

- Satta, Giuseppe, 678
 Saukkonen, Jussi J., 200
 Sawai, Tetsuo, 227
 Sawatari, Katsuhiko, 15
 Schaberg, Dennis R., 446
 Schaeffer, Henry A., 149
 Scheld, W. Michael, 361, 428
 Schinazi, Raymond F., 552
 Schleupner, Charles J., 146
 Schmidt, L. H., 612
 Schulemann, Werner, 612
 Scoreaux, B., 37
 Scott, R. Taylor, 552
 Scribner, Ronald K., 58
 Sedlock, David M., 786
 Seger, R., 667
 Selman, Warren R., 839
 Shanley, John D., 172
 Shermantine, Maria, 535
 Sheth, Nitin V., 103
 Sheu, Michael J.-T., 626
 Shigeno, Yoshiteru, 15
 Shimizu, Kihachiro, 282
 Shockley, Thomas E., 21
 Shull, Virginia H., 597
 Siber, George R., 107
 Sidwell, Robert W., 375
 Silcox, Vella A., 807
 Siler, William, 265
 Skidmore, A. G., 259
 Skog, Sven, 802
 Slaney, Leslie, 393
 Smee, Donald F., 240
 Smith, A., 259
 Smith, Arnold L., 74
 Smith, Bruce R., 133
 Smith, J. A., 259
 Smith, Sharon M., 601
 Soriano, Francisco, 845
 Spruance, Spotswood L., 103
 Spyker, Daniel A., 216
 Srulevitch, Elina S., 706
 Stamm, Walter E., 188
 Stanforth, David, 796
 Stenberg, Kjell, 802
 Stoltzman, David S., 33
 Stone, Benjamin B., 64
 Stratton, Charles W., 41
 Strunk, Roger W., 428
 Suarez, J. E., 163
 Sud, Inder J., 532
 Suen, Hon-Chi, 639
 Sullivan, Roger, 612
 Sunila, Ritva, 354
 Süssmuth, Roland, 456
 Sutton, Lorraine, 703
 Suzuki, Satoru, 326
 Suzuyama, Yoji, 15
 Swenson, Jana M., 807
 Tadakuma, Takushi, 28
 Takahashi, Katsuhiko, 5
 Takai, Akira, 773
 Tally, Francis P., 675
 Tanaka, Michiyasu, 227
 Tansino, Gary F., 508
 Tarbit, M. H., 648
 Tausk, Francisca, 41
 Taveres, Aida, 361
 Taylor, Diane E., 452, 708
 Tenney, James H., 442
 Tenover, Fred C., 69
 Textor, Jacquelyn A., 691
 Thabet, Michel, 349
 Thauvin, Claudie, 78
 Thirumoorathi, M. C., 138
 Thompson, Bruce, 735
 Thornsberry, Clyde, 154, 807
 Thys, J. P., 467
 Ti, Teow-Yee, 540
 Toivanen, Paavo, 354
 Tolkooff-Rubin, N. E., 46
 Tolxdorff-Neutzling, Regina M., 302
 Tomonaga, Akimitsu, 15
 Torney, Harry L., 745
 Townsend, Paula L., 829
 Trang, John M., 791
 Tribukait, Bernhard, 802
 Troke, Peter F., 815
 Trown, Patrick W., 1
 Tsai, Y. H., 761
 Tsuboi, Minoru, 192
 Tsutsumi, Masayoshi, 28
 Tuazon, Carmelita U., 576
 Turchetti, Gianni, 419
 Turgeon, Pierre L., 711
 Underwood, Fred L., 791
 Utsui, Yukio, 397
 Vallee, François, 713
 Vallois, Jean-Marie, 607
 van den Berg, Joke C., 654
 Van der Auwera, P., 37, 467
 Vanderhaeghe, Hubert, 630
 Van der Linden, M. P., 756
 Varghese, Mathew, 149
 Verbist, Ludo, 630
 Vertut-Croquin, Aline, 167
 Vidon, Dominique J.-M., 351
 Viitanen, J., 812
 Villar, C. J., 163
 Vincenti, Flavio, 535
 Vosbeck, K., 667
 Vree Tom B., 654
 Wagner, Robin L., 832
 Walder, Mats H., 12
 Wallace, Richard J., Jr., 807
 Wallace, Sylvia M., 274
 Walzer, Peter D., 796
 Warren, H. Shaw, 107
 Weber, Allan, 74
 Weber, Andrew H., 58
 Weisser, Jochen, 700
 Wells, Thomas G., 791
 Wennersten, Christine, 78
 White, Robert A., 511
 Whitley, Richard J., 265
 Wiedemann, Bernd, 302, 700
 Wilhelmi, Isabel, 845
 Williams, Keith, 824
 Williamson, Joanne M., 478
 Williams-Warren, Judy, 74
 Wilson, P., 211
 Wise, R., 425, 837
 Wolcott, Judith A., 485
 Wolfson, John S., 581, 716
 Wong, Kwok-Kee, 639
 Wong, P. C. L., 461
 Woodard, David R., 33
 Woolfrey, Bert F., 381
 Wrzos, Helena, 449
 Yamaguchi, Keizo, 15
 Yamamoto, Tomoko, 227
 Yasuda, Takashi, 773
 Yasuda, Tatsuji, 28
 Yazawa, Katsukiyo, 5
 Yim, Connie Whiteside, 347
 Yin-Murphy, Marguerite, 578
 Yiu, Tim-Fuk, 639
 Yokota, Takeshi, 397
 Yoshida, Shonen, 326
 Yost, Richard L., 727
 Yotsuji, Akira, 773
 Young, Stephen A., 69
 Yourassowsky, E., 756
 Yu, Victor L., 832
 Zak, Oto, 195
 Zeiler, H.-J., 52
 Zervos, Marcus J., 446
 Zinner, Stephen H., 64

SUBJECT INDEX VOLUME 28

- A-56619**
activity in vitro, 514
- A-56620**
activity in vitro, 514
- Absorption**
oral ampicillin, 727
- Acyclovir**
cytomegalovirus, 172, 240
experimental infections
herpes simplex virus, 1
herpes simplex virus, 103
resistance patterns, 740
lung infection, 172
pneumonitis, 172
- Adjuvants**
cefazolin rectal absorption, 211
- Aerobic bacteria**
SK&F 88070, 343
- Aeromonas caviae**
susceptibility, 151
- Aeromonas hydrophila**
susceptibility, 151
- Aeromonas sobria**
susceptibility, 151
- Amantadine hydrochloride**
pharmacokinetics, 216
- Aminocillin**
pharmacokinetics, 46
renal insufficiency, 46
- Amikacin**
combinations
cefazidime, 781
endocarditis, 607, 781
enterococci, 78
penicillin, 78, 607
vancomycin, 607
comparative activity
cefazidime, 735
piperacillin, 735
endocarditis, 607, 781
experimental infections
endocarditis, 607
P. aeruginosa, 735
P. aeruginosa
endocarditis, 781
P. aeruginosa experimental infections, 735
- Amiloride**
antistreptococcal activity, 419
- Aminoglycoside**
interaction with β -lactam penicillins, 274
- Aminoglycosides**
2''-O-adenylyltransferase, 69
DNA hybridization, 69
phosphotransferases
H. ducreyi, 311
plasmid-mediated, 311
resistance patterns, 282
- Amoxicillin**
combinations
clavulanic acid, 165
penetration into pelvic peritoneum, 165
- Amoxicillin-clavulanic acid**
comparative activity
co-trimoxazole, 693
urinary tract infections, 693
urinary tract infections, 693
- Amphotericin B**
C. albicans, 751
- candidiasis**, 511
- C. neoformans***, 751
- combinations**
muramyl dipeptide analog, 511
- experimental infections**
C. albicans endocarditis, 751
cryptococcal meningitis, 751
- lipoprotein-complexed**
serum cholesterol elevation, 144
toxicity, 144
- liposome-encapsulated**
candidiasis, 511
- transfer from gel state vesicles**, 167
- Ampicillin**
absorption
lactobacillus effects, 727
- combinations**
penetration into pelvic peritoneum, 165
- sulbactam**, 165
- Corynebacterium* group D2**, 845
- E. coli***
suprainhibitory concentrations, 756
- H. influenzae***, 404
- mice**
morphine effects
- penetration**
fibrin clots, 404
interstitial fluid, 404
- pharmacokinetics**
morphine effects, 489
- resistance**
N. gonorrhoeae, 21
- Ampicillin-chloramphenicol**
experimental infections
E. coli bacteremia, 433
meningitis, 433
- Ampicillin-gentamicin**
experimental infections
E. coli bacteremia, 433
meningitis, 433
- Ansamycin**
comparative activity
MDL 473, 440
rifampin, 440
- Mycobacterium avium* complex**
MICs, 570
- Mycobacterium intracellulare***, 440
- Antileishmanial drugs**
activity in vitro
semiautomated assessment, 723
- Antineoplastic agents**
antibacterial activities, 437
- Antiprotozoal drugs**
Giardia lamblia, 378
- Antistreptococcal activity**
amiloride, 419
triamterene, 419
- Appendicitis**
 β -lactams
treatment, 639
- 1- β -D-Arabinofuranosyl-5-fluorouracil**
cytomegalovirus inhibition, 326
- Arabinosyladenine**
high-pressure liquid chromatography, 265
- Arabinosyladenine-5'-monophosphate**
high-pressure liquid chromatography, 265
- Arabinosylhypoxanthine**
high-pressure liquid chromatography, 265
- Aridicins**
activities, 660
- Arildone**
acute hemorrhagic conjunctivitis viruses, 578
- combinations**
interferon, 578
- Azlocillin**
combinations
ciprofloxacin, 849
- Aztreonam**
bacterial infections, 222
H. influenzae, 404
penetration
fibrin clots, 404
interstitial fluid, 404
- Bacteremia**
BMJ-28142, 51
cefazidime, 33
E. coli, 51
group B streptococci, 51
ticarcillin, 33
tobramycin, 33
- Bacterial infections**
aztreonam, 222
- Bacteroides fragilis***
cephamycin
 β -lactamase inactivation, 773
cephamycin inactivation, 733
2-methyl-5-nitroimidazole compounds
carnidazole, 562
dimetridazole, 562
metronidazole, 562
ornidazole, 562
panidazole, 562
secnidazole, 562
tinidazole, 562
susceptibility
nationwide study, 675
- Bacteroides uniformis***
chloramphenicol resistance, 113
R plasmid, 113
- Biliary excretion**
piperacillin, 778
- BMJ-28142**
bacteremia, 51
cystic fibrosis isolates, 58
E. coli, 51
group B streptococci, 51
meningitis, 51
pediatric pathogens, 58
- Campylobacter coli***
macrolides, 695
- Campylobacter jejuni***
clavulanic acids, 37
 β -lactams, 37
macrolides, 695
sulbactam, 37
- Campylobacter*-like organisms**
susceptibility, 188
- Campylobacter pyloridis***
susceptibility, 837
- Campylobacter* spp.**
susceptibility
DNA gyrase inhibitors, 708

- enoxacin, 708
 nalidixic acid, 708
Candida albicans
 experimental infections
 mice, 815
 UK-49, 858, 815
 lornazepam, 643
 peptidyl drug transport rates, 494
 UK-49, 858
 mice, 815
 ultrastructure
 lornazepam, 643
Candidiasis
 amphotericin B
 liposome-encapsulated, 511
 prophylaxis, 511
Carnidazole
Bacteroides spp., 562
 comparative activity
 2-methyl-5-nitroimidazole compounds, 562
Carumonam
 comparative activity, 834
 pharmacokinetics, 425
 tissue penetration, 425
Cefamandole
 comparative activity
 ceftazidime, 146
 pneumonia, 146
Cefazolin
 experimental infections
 K. pneumoniae pneumonia in rats, 654
 K. pneumoniae, 654
 serum protein binding
 K. pneumoniae pneumonia in rats, 654
Cefmenoxime
 children
 clinical efficacy, 508
 safety, 508
 experimental infections
 E. coli bacteremia, 389
 meningitis, 389
Cefmetazole
 pharmacokinetics
 intramuscular administration, 544
 intravenous administration, 544
Cefoperazone
 infants
 pharmacokinetics, 149
 serum bactericidal activity, 55
Cefotaxime
 cerebrospinal fluid diffusion, 138
 comparative activity
 ceftazidime, 160
 ceftazidime, 160
 desacetylcefotaxime, 791
 enterococci, 160
 experimental infections
 E. coli bacteremia, 433
 meningitis, 433
 meningitis, 138
 pharmacokinetics, 791
 P. aeruginosa, 160
 pharmacokinetics
 meningitis, 791
 S. aureus, 160
 S. epidermidis, 160
 serum bactericidal activity, 55
Cefotiam
 lower respiratory tract infections, 576
Cefoxitin
 adjuvants, 211
 experimental infections
 K. pneumoniae pneumonia in rats, 654
 K. pneumoniae, 654
 rectal absorption, 211
 serum protein binding
 K. pneumoniae pneumonia in rats, 654
Cefpimizole
 comparative activity, 133
 in vitro evaluation, 133
Cefpirome
 comparative activity
 cefotaxime, 160
 ceftazidime, 160
 enterococci, 160
 P. aeruginosa, 160
 S. aureus, 160
 S. epidermidis, 160
Ceftazidime
 bacteremia, 33
 clinical comparisons, 299
 combinations
 amikacin, 781
 endocarditis, 781
 flucloxacillin, 824
 in vitro pharmacokinetics, 64
 netilmicin, 64
 P. aeruginosa, 64
 comparative activity
 amikacin, 735
 cefamandole, 146
 cefotaxime, 160
 ceftazidime, 160
 piperacillin, 735
 endocarditis
 P. aeruginosa, 781
 enterococci, 160
 experimental infections
 P. aeruginosa, 735
 neutropenic patients
 empiric treatment, 824
 flucloxacillin combination, 824
 P. aeruginosa, 160
 endocarditis, 781
 P. aeruginosa experimental infections, 735
 pharmacokinetics
 elderly humans, 713
 pneumonia, 33, 146
 S. aureus, 160
 S. epidermidis, 160
 urinary tract infections, 299
Ceftizoxime
 serum bactericidal activity, 55
Ceftriaxone
 blister fluid penetration, 123
 comparative activity
 ampicillin plus chloramphenicol, 361
 meningitis, acute bacterial, 361
 typhoid fever, 540
Cefuroxime
H. influenzae, 404
 penetration
 fibrin clots, 404
 interstitial fluid, 404
Cefuroxime axetil
 bactericidal activity, 504
 pharmacokinetics, 504
Cephalosporins
K. pneumoniae surface antigens, 195
 pharmacokinetics
 septicemic rabbits, 473
 resistance
 plasmid-coded, 302
Cephalothin
Corynebacterium group D2, 845
Cepharmycin
B. fragilis
 β -lactamase inactivation, 773
CGP 11637
 experimental infections
 oncogenic viruses, 589
 oncogenic viruses, 589
Chloramphenicol
B. uniformis resistance, 113
 resistance
 H. ducreyi, 176
 H. parainfluenzae, 176
 5-(2-Chloroethyl)-2'-deoxyuridine
 herpes simplex virus, 246
CI-934
 in vitro activity, 766
Cilastatin
 superoxide dismutase activity, 691
Ciprofloxacin
 aminoglycoside combinations, 663
 biliary elimination, 311
 clinical efficacy, 128
 combinations
 aminoglycosides, 663
 azlocillin, 849
 Enterobacteriaceae, 663
 P. aeruginosa, 663
 comparative activity
 azlocillin plus tobramycin, 428
 P. aeruginosa endocarditis, 428
 E. coli, 331
 high-pressure liquid chromatography, 311
 log-phase *E. coli*, 524
 methicillin resistance
 S. aureus, 634
 microbiological assay, 311
 oral formulations, 74
 P. aeruginosa, 308, 331, 428
 pharmacokinetics, 74, 235
 S. aureus, 331
 synergy, 331
Clavulanic acid
C. jejuni, 37
 combinations
 amoxicillin, 165
 comparative activity, 259
 penetration into pelvic peritoneum, 165
 ticarcillin, 259
Clostridium difficile
 β -lactams, 842
 quinolones, 842
 teicoplanin, 847
 vancomycin, 847
Colistin nonapeptide
 lipopolysaccharides
 binding, 107
 neutralization, 107
Continuous ambulatory peritoneal dialysis
 moxalactam kinetics, 293
Corynebacterium group D2
 ampicillin, 845
 cephalothin, 845
 erythromycin, 845
 gentamicin, 845
 norfloxacin, 845

- novobiocin, 845
rifampin, 845
tetracycline, 845
vancomycin, 845
- Co-trimoxazole
comparative activity
amoxicillin-clavulanic acid, 693
urinary tract infections, 693
urinary tract infections, 693
- Coumermycin
comparative activity
S. aureus, 706
methicillin resistance
S. aureus, 634
S. aureus
methicillin-resistant, 706
- Cystic fibrosis
BMJ-28142, 58
netilmicin pharmacokinetics, 829
- Cytomegalovirus
acyclovir, 240
1- β -D-arabinofuranosyl-5-fluorouracil, 326
2'-deoxy-2'-fluoro- β -D-arabinofuranosyl-5-iodocytosine, 252
9-(1,3-dihydroxy-2-propoxymethyl) guanine, 240
human skin fibroblasts, 252
murine
acyclovir, 172
9-(1,3-dihydroxy-2-propoxymethyl) guanine, 172
interstitial pneumonitis, 172
lung infection, 172
pyrimidine treatment, 485
selective inhibition, 326
- 2'-Deoxy-2'-fluoro- β -D-arabinofuranosyl-5-iodocytosine
cytomegalovirus, 252
human skin fibroblasts, 252
- Desacetylcefotaxime
cefotaxime, 791
meningitis
pharmacokinetics, 791
pharmacokinetics
meningitis, 791
- Dibekacin
HPLC
determination in serum, 521
- Diffusional clearance model, 369
- 9-(1,3-Dihydroxy-2-propoxymethyl) guanine
comparative activity, 240
cytomegalovirus, 172, 240
lung infection, 172
pneumonitis, 172
- Dimetridazole
Bacteroides spp., 562
comparative activity
2-methyl-5-nitroimidazole compounds, 562
- DNA gyrase inhibitors
Campylobacter spp.
comparative activity
Campylobacter spp., 708
enoxacin, 708
nalidixic acid, 708
E. coli, 200
- DNA hybridization
aminoglycoside
2''-O-adenylyltransferase, 69
- Doxycycline
syphilis, 347
- Endocarditis
ciprofloxacin
P. aeruginosa, 428
combinations
amikacin-ceftazidime, 781
P. aeruginosa
amikacin, 781
ceftazidime, 781
ciprofloxacin, 428
- Enoxacin
Campylobacter spp., 708
comparative activity, 259
Campylobacter spp., 708
DNA gyrase inhibitors, 708
nalidixic acid, 708
- Enterobacteriaceae
ciprofloxacin-aminoglycoside combinations, 663
 β -lactams
inoculum effect, 601
- Enterococci
amikacin, 78
cefotaxime, 160
ceftazidime, 160
ceftazidime, 160
penicillin, 78
trimethoprim-sulfamethoxazole susceptibility
susceptibility reversal by folinic acid, 446
- Enzyme-linked immunosorbent assays
infected cell monolayers, 207
varicella-zoster virus, 207
- Enzymuria
gentamicin, 500
tobramycin, 500
- Erythromycin
Corynebacterium group D2, 845
- Erythromycins
A through D
MICs, 630
- Escherichia coli*
ampicillin
suprainhibitory concentrations, 756
bacteremia, 51
BMJ-28142, 51
cefmenoxime, 389
ciprofloxacin, 331
DNA gyrase inhibitors, 200
experimental infections
ampicillin-chloramphenicol, 433
ampicillin-gentamicin, 433
bacteremia, 389, 433
cefmenoxime, 389
cefotaxime, 433
imipenem-cilastatin, 433
 β -lactamases, 703
 β -lactam resistance, 703
log phase
ciprofloxacin, 524
membrane permeability, 200
meningitis, 51
piperacillin
suprainhibitory concentrations, 756
stationary phase
ciprofloxacin, 524
- Ethambutol
dextro isomer, 157
Mycobacteria spp. spermidine synthesis, 157
- 5-Ethyl-2'-deoxyuridine
experimental infections
herpes simplex virus, 552
herpes simplex virus, 103, 552
- Experimental infections
C. albicans endocarditis, 751
cryptococcal meningitis, 751
E. coli bacteremia
ampicillin-chloramphenicol, 433
ampicillin-gentamicin, 433
cefmenoxime, 389
cefotaxime, 433
imipenem-cilastatin, 433
interferon, 1
endocarditis
amikacin, 781
ceftazidime, 781
herpes simplex virus
acyclovir, 1
5-ethyl-2'-deoxyuridine, 552
interferon, 1
Legionella micdadei, 730
meningitis
ampicillin-chloramphenicol, 433
ampicillin-gentamicin, 433
cefmenoxime, 389
cefotaxime, 433
imipenem-cilastatin, 433
oncogenic viruses
CGP 11637, 589
P. aeruginosa
amikacin, 781
ceftazidime, 781
endocarditis, 781
phosphanilic acid, 761
picornavirus
phenoxypyridinecarbonitriles, 745
- Feline calcivirus
interferon, 698
- Feline herpesvirus 1
interferon, 698
- Fibroblasts
human skin
cytomegalovirus, 252
2'-deoxy-2'-fluoro- β -D-arabinofuranosyl-5-iodocytosine, 252
- Flucloxacillin
combinations
ceftazidime, 824
neutropenic patients
ceftazidime combination, 824
- Fluoroquinolones
activity spectra, 581
clinical uses, 716
mechanisms of action, 581
mechanisms of resistance, 581
pharmacology, 716
structures, 581
toxicities, 716
- Folinic acid
enterococci
reversal of trimethoprim-sulfamethoxazole susceptibility, 446
- Foscarnet
cell cycle
concentration-dependent effects, 802
- Fosfomycin
combinations
S. aureus, 689
enzymatic modification, 163
plasmid-mediated resistance, 163
S. aureus
methicillin-resistant, 689

- Gene probes
gentamicin resistance, 96
TEM β -lactamases, 154
- Gentamicin
N-acetyl- β -D-glucosaminidase excretion
tobramycin comparison, 500
combinations
endocarditis, 607
penicillin, 607
vancomycin, 607
Corynebacterium group D2, 845
endocarditis, 607
experimental infections
endocarditis, 607
fetal tissues
guinea pigs, 565
kinetics
guinea pigs, 565
resistance
gene probe, 96
- Germicidal agents
octenidine hydrochloride, 786
- Giardia lamblia*
antiprotozoal drugs, 378
- Haemophilus ducreyi*
aminoglycoside phosphotransferase, 311
chloramphenicol-resistant, 176
molecular characterization, 176
- Haemophilus influenzae*
ampicillin, 404
aztreonam, 404
cefuroxime, 404
 β -lactams, 320
SK&F 88070, 343
tolerance, 320
- Haemophilus parainfluenzae*
chloramphenicol-resistant, 176
molecular characterization, 176
- 5-(2-Haloalkyl)pyrimidine
nucleoside analogs
herpes simplex virus, 246
- Herpes simplex virus
acyclovir, 103
resistance patterns, 740
5-(2-chloroethyl)-2'-deoxyuridine, 246
5-ethyl-2'-deoxyuridine, 103
experimental infections
acyclovir, 1
5-ethyl-2'-deoxyuridine, 552
interferon, 1
5-(2-haloalkyl)pyrimidine nucleoside analogs, 246
nonoxynol 9, 449
interferon, 449
plaque autoradiography assay, 181
thymidine kinase mutants, 181
- High-pressure liquid chromatography
arabinosyladenine, 265
arabinosyladenine-5'-monophosphate, 265
arabinosylhypoxanthine, 265
ciprofloxacin, 311
comparative studies, 311
dibekacin
determination in serum, 521
kanamycin
determination in serum, 521
pipemidic acid, 192
ticarcillin, 597
- HR 810
see cefpirome
- Human brucellosis
rifampin-doxycycline, 548
tetracycline-streptomycin, 548
- Imipenem
comparative activity, 259
P. aeruginosa resistance, 41
stability
Mueller-Hinton agar at 4°C, 711
- Imipenem-cilastatin
experimental infections
E. coli bacteremia, 433
meningitis, 433
- Influenza viruses A and B
selenazofurin, 375
- Interferon
combinations
aridone, 578
experimental infections
herpes simplex virus, 1
feline
feline calicivirus, 698
feline herpesvirus 1, 698
nonoxynol 9
synergy against herpes simplex virus
type 2, 449
recombinant human leukocyte
feline calicivirus, 698
feline herpesvirus 1, 698
- Kanamycin
HPLC
determination in serum, 521
- Ketoconazole
combinations
sterol synthesis inhibitors, 532
fungal growth, 532
- Klebsiella pneumoniae*
cefazolin, 654
cefoxitin, 654
cephalosporins, 195
experimental infections
cefazolin, 654
cefoxitin, 654
rats, 654
protein antigens, 195
- β -Lactamase
B. fragilis
cephamycin inactivation, 773
E. coli, 703
gene probe, 154
OXA-1
transposon, 227
TEM type, 154
- β -Lactams
appendicitis
treatment, 639
C. difficile, 842
C. jejuni, 37
diffusional clearance model, 369
Enterobacteriaceae
inoculum effect, 601
H. influenzae, 320
N. gonorrhoeae resistance, 90
P. aeruginosa resistance, 41
penicillin-binding proteins, 678
penicillins
interaction with aminoglycosides, 274
pharmacokinetics, 369
resistance
E. coli, 703
- S. faecium*
hypersusceptibility, 678
- Legionella micdadei*
experimental infections, 730
- Legionella pneumophila*
experimental infections
pneumonia, 15
ofloxacin, 15
- Leishmania* spp.
multiplication
sinefungin, 528
- Leuconostoc* sp.
vancomycin resistance, 458
- Lichen metabolites
antimicrobial activity, 289
- Lincomycin
S. haemolyticus
plasmid-mediated resistance, 421
- Lipopolysaccharides
binding, 107
colistin nonapeptide, 107
neutralization, 107
- Lipoproteins
amphotericin B
serum cholesterol elevation, 144
toxicity, 144
- Listeria monocytogenes*
susceptibility, 12
- Lombazole
C. albicans
ultrastructure, 643
S. epidermidis
ultrastructure, 643
- Lung infections
acyclovir, 172
cytomegalovirus, 172
9-(1,3-dihydroxy-2-propoxymethyl) guanine, 172
- Macrolides
C. coli, 695
C. jejuni, 695
- Malaria
RC-12, 612
- MCP-1
cytotoxicity for tumor cells, 626
- MCP-2
cytotoxicity for tumor cells, 626
- MDL 473
comparative activity
ansamycin, 440
rifampin, 440
Mycobacterium intracellulare, 440
- Meningitis
BMJ-28142, 51
cefotaxime, 138
ceftriaxone, 361
E. coli, 51
experimental infections
ampicillin-chloramphenicol, 433
ampicillin-gentamicin, 433
cefmenoxime, 389
cefotaxime, 433
imipenem-cilastatin, 433
group B streptococci, 51
- Metronidazole
Bacteroides spp., 562
comparative activity
2-methyl-5-nitroimidazole compounds, 562
genital tissue concentrations, 812
- Microbiological assays
ciprofloxacin, 311

- comparative studies, 311
- Morphine**
ampicillin disposition, 489
- Moxalactam**
cerebrospinal fluid penetration
ventriculostomy patients, 839
clinical comparisons, 299
continuous ambulatory peritoneal dialysis, 293
kinetics, 293
serum bactericidal activity, 55
urinary tract infections, 299
- Muramyl dipeptide analog**
candidiasis, 511
combinations
amphotericin B, 511
- Mycobacteria**
rapidly growing, 807
ethambutol, 157
spermidine synthesis, 157
- Mycobacterium avium* complex**
ansamycin
MICs, 570
- Mycobacterium chelonae***
subgroups, 807
- Mycobacterium fortuitum***
subgroups, 807
- Mycobacterium intracellulare***
ansamycin, 440
MDL 473, 440
rifampin, 440
- Mycoplasma hominis***
streptococcal *tetM* sequences, 141
tetracycline resistance, 141
- Mycoplasma* spp.**
amphotericin B transfer, 167
permeability, 167
potassium transport, 167
- Nalidixic acid**
Campylobacter spp., 708
comparative activity
Campylobacter spp., 708
DNA gyrase inhibitors, 708
enoxacin, 708
- Neisseria gonorrhoeae***
ampicillin resistance, 21
 β -lactam resistance, 90
Ophthalmia neonatorum isolates, 393
penicillin-binding proteins, 90
peptidoglycan structure, 90
Ro 15-8074, 461
susceptibility
ophthalmia neonatorum isolates, 393
- Neplanocins**
antimetabolic activities, 84
antiviral activities, 84
- Netilmicin**
combinations
ceftazidime, 64
in vitro pharmacokinetics, 64
P. aeruginosa, 64
dosage requirements
cystic fibrosis patients, 829
pharmacokinetics
cystic fibrosis patients, 829
- Nonoxynol 9**
interferon
synergy against herpes simplex virus
type 2, 449
- Norfloxacin**
Corynebacterium group D2, 845
tissue penetration, 349
- Novobiocin**
Corynebacterium group D2, 845
- Obstructive jaundice**
piperacillin, 778
- Octenidine hydrochloride**
germicide agent, 786
- Ofloxacin**
L. pneumophila, 15
pneumonia, 15
- Oncogenic virus infections**
prevention
CGP 11637, 589
- Ophthalmia neonatorum**
N. gonorrhoeae isolates
susceptibility, 393
- Ornidazole**
Bacteroides spp., 562
comparative activity
2-methyl-5-nitroimidazole compounds, 562
- N-D-Ornithyl amphotericin B**
C. albicans, 751
C. neoformans, 751
experimental infections
C. albicans endocarditis, 751
cryptococcal meningitis, 751
- Oxacillin**
combinations
rifampin, 467
placebo-controlled study, 467
rifampin
staphylococcal infections, 467
staphylococcal infections
rifampin, 467
Staphylococcus aureus
tolerance, 381
- Panidazole**
Bacteroides spp., 562
comparative activity
2-methyl-5-nitroimidazole compounds, 562
- Pediatric infections**
cefmenoxime
clinical efficacy, 508
safety, 508
- Pediatric pathogens**
BMV-28142, 58
- Penicillin**
combinations
amikacin, 78, 607
endocarditis, 607
enterococci, 78
gentamicin, 607
comparative activity
vancomycin, 607
endocarditis, 607
experimental infections
endocarditis, 607
- Penicillin-binding protein**
S. aureus
cephem-resistant, 397
methicillin-resistant, 397
- Penicillin-binding proteins**
 β -lactam hypersusceptibility, 678
N. gonorrhoeae, 90
S. faecium, 678
- Peptidoglycans**
N. gonorrhoeae, 90
- Peptidyl drugs**
transport rates
C. albicans, 494
- Pharmacokinetics**
amantadine hydrochloride, 216
amdinocillin, 46
ampicillin
morphine effects, 489
 β -lactams, 369
carumonam, 425
cefmetazole, 544
cefoperazone, 149
ceftazidime
elderly humans, 713
cephalosporins
rabbits, 473
ciprofloxacin, 74, 235
netilmicin
cystic fibrosis patients, 829
rimantadine hydrochloride, 216
sulfoxazole
renal transplant patients, 535
sultamicillin, 832
UK-49,858, 648
- Phenoxypyridine carbonitriles**
antipicornavirus activity, 745
- Phosphonic acid**
combinations
trimethoprim, 761
- Picornaviruses**
experimental infections, 745
phenoxypyridine carbonitriles, 745
- Pipemidic acid**
high-pressure liquid chromatography, 192
- Piperacillin**
Biliary excretion, 778
comparative activity, 259
amikacin, 735
ceftazidime, 735
E. coli
suprainhibitory concentrations, 756
experimental infections
P. aeruginosa, 735
obstructive jaundice, 778
P. aeruginosa experimental infections, 735
- Plaque autoradiography**
herpes simplex virus, 181
- Plasmids**
elimination
4-quinolones, 700
gram-negative bacteria, 413
multiply resistant
molecular analysis, 413
resistance
cephalosporins, 302
Salmonella typhi, 452
S. haemolyticus, 421
Salmonella typhi
IncH11 variability, 452
trimethoprim resistance, 452
- Pneumocystis carinii***
susceptibility test, 796
- Pneumonia**
cefamandole, 146
ceftazidime, 33, 146
L. pneumophila, 15
ofloxacin, 15
ticarcillin, 33
tobramycin, 33
- Pneumonitis**
acyclovir, 172
cytomegalovirus, 172
9-(1,3-dihydroxy-2-propoxymethyl) guanine, 172

- Polymorphonuclear leukocytes
rifampin, 667
- Protein binding
cefazolin, 654
cefotaxime, 654
- Pseudomonas aeruginosa*
cefotaxime, 160
ceftazidime, 160
ceftazidime, 64, 160
ciprofloxacin, 308, 331, 428
ciprofloxacin-aminoglycoside combinations, 663
endocarditis
ciprofloxacin, 428
netilmicin, 64
resistance
imipenem, 41
 β -lactams, 41
- Pyrimidine
cytomegalovirus infection, 485
- Quinolones
A-56619, 514
A-56620, 514
C. difficile, 842
- 4-Quinolones
plasmid elimination, 700
- Rabbit macrophage peptides
MCP-1
cytotoxicity for tumor cells, 626
MCP-2
cytotoxicity for tumor cells, 626
- RC-12
antimalarial activity, 612
subacute toxicity, 612
- Renal insufficiency
amoxicillin pharmacokinetics, 46
- Resistance
B. fragilis
nationwide study, 675
- Respiratory tract infections
cefotiam, 576
- Rifampin
combinations
oxacillin, 467
comparative activity
ansamycin, 440
MDL 473, 440
Corynebacterium group D2, 845
Mycobacterium intracellulare, 440
oxacillin
staphylococcal infections, 467
placebo-controlled study, 467
polymorphonuclear leukocytes, 667
staphylococcal infections, 467
oxacillin, 467
- Rifampin-doxycycline
human brucellosis, 548
- Rimantadine hydrochloride
pharmacokinetics, 216
- Ro 15-8074
N. gonorrhoeae, 461
- Saframycin
derivatives
biosynthesis, 5
S. lavendulae, 5
- Salmonella enteritidis
salmonellosis, 28
streptomycin, 28
- Salmonella typhi
trimethoprim resistance
- IncH11 plasmid, 452
- Salmonellosis
S. enteritidis, 28
streptomycin, 28
- Sch 34343
activity, 684
stability
 β -lactamases, 684
renal dehydropeptidase 1, 684
- Secnidazole
Bacteroides spp., 562
comparative activity
2-methyl-5-nitroimidazole compounds, 562
- Selenazofurin
influenza A and B viruses, 375
- Sinefungin
Leishmania spp.
effect on multiplication, 528
- SK&F 88070
aerobic cocci, 343
H. influenzae, 343
- Sodium hypochlorite
antimicrobial activity, 118
chemical parameters, 118
tissue toxicity, 118
- Spermidine
synthesis, 157
- Staphylococcus aureus
cefotaxime, 160
ceftazidime, 160
ceftazidime, 160
cephem-resistant
penicillin-binding protein, 397
ciprofloxacin, 331
coumermycin, 706
fosfomicin, 689
methicillin-resistant
ciprofloxacin, 634
coumermycin, 634, 706
penicillin-binding protein, 397
septicemia, 819
teicoplanin, 634
oscillating tolerance in synchronized cultures, 456
oxacillin tolerance, 381
- Staphylococcus epidermidis
cefotaxime, 160
ceftazidime, 160
ceftazidime, 160
lombazole, 643
ultrastructure
lombazole, 643
- Staphylococcus haemolyticus
lincomycin
plasmid-mediated resistance, 421
- Streptococci
group B
bacteremia, 51
BMY-28142, 51
meningitis, 51
tetM sequences
M. hominis, 141
vancomycin resistance, 458
- Streptococcus faecium
hypersusceptibility, 678
 β -lactams
hypersusceptibility, 678
low-affinity penicillin-binding proteins, 678
resistance
transition to hypersusceptibility, 678
- Streptococcus pneumoniae
resistance, 357
serotypes, 357
- Streptomyces cattleya
reverse transsulfuration
thienamycin biosynthesis, 478
- Streptomyces lavendulae
saframycin biosynthesis, 5
- Streptomycin
salmonellosis, 28
S. enteritidis, 28
- Sulbactam
C. jejuni, 37
combinations
ampicillin, 165
penetration into pelvic peritoneum, 165
- Sulfisoxazole
pharmacokinetics
renal transplant patients, 535
- Sultamicillin
pharmacokinetics, 832
sinusitis
pharmacokinetics, 832
therapeutic trial, 832
therapeutic trial, 832
- Superoxide dismutase
cilastatin, 691
- Susceptibility testing
N. gonorrhoeae, 393
- Syphilis
doxycycline, 347
- Teicoplanin
C. difficile, 847
cholestyramine interactions, 847
comparative activity
vancomycin, 847
methicillin resistance
S. aureus, 634
- Tetracycline
Corynebacterium group D2, 845
M. hominis resistance, 141
- Tetracycline-streptomycin
human brucellosis, 548
- Thienamycin
S. cattleya
reverse transsulfuration, 478
- Ticarcillin
combinations
bacteremia, 33
clavulanic acid, 259
comparative activity, 259
pneumonia, 33
ticarcillin, 33
HPLC determination, 597
- Tinidazole
Bacteroides spp., 562
comparative activity
2-methyl-5-nitroimidazole compounds, 562
genital tissue concentrations, 812
- Tissue fluid kinetics
diffusional clearance model, 369
- Tissue penetration
carumonam, 425
- Tobramycin
N-acetyl- β -D-glucosaminidase excretion
gentamicin comparison, 500
combinations
bacteremia, 33
pneumonia, 33
ticarcillin, 33

- Triamterene
 antistreptococcal activity, 419
- Triazoles
 UK-49,858
 pharmacokinetics, 648
- Trimethoprim
 combinations
 phosphanilic acid, 761
 resistance in fecal flora, 354
 resistance plasmids
 Salmonella typhi, 452
- Trimethoprim-sulfamethoxazole
 enterococci
 susceptibility reversal by folinic acid, 446
 folinic acid
 susceptibility reversal, 446
- Tumor cells
 mice
 MCP-1, 626
 MCP-2, 626
- Typhoid fever
 ceftriaxone therapy, 540
- U-63196E
 see cefpimizole
- UK-49,858
 C. albicans
 mice, 815
 experimental infections
 C. albicans, 815
 mice, 815
 pharmacokinetics
 animals, 648
 humans, 648
- Urinary tract infections
 ceftazidime, 299
 moxalactam, 299
- Vancomycin
 C. difficile, 847
 cholestyramine interactions, 847
 combinations
 amikacin, 607
 endocarditis, 607
 gentamicin, 607
 comparative activity
 penicillin, 607
 teicoplanin, 847
- Corynebacterium* group D2, 845
 endocarditis
 experimental infections
 endocarditis, 607
- Varicella-zoster virus
 enzyme-linked immunosorbent assay, 207
 infected cell monolayers, 207
- Vibrio* spp.
 norfloxacin, 442
- Yersinia enterocolitica*
 susceptibility, 351
- Yersinia frederiksenii*
 susceptibility, 351
- Yersinia intermedia*
 susceptibility, 351
- Yersinia kristensenii*
 susceptibility, 351

